See more : Wihlborgs Fastigheter AB (publ) (WIHLY) Income Statement Analysis – Financial Results
Complete financial analysis of Dyadic International, Inc. (DYAI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dyadic International, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Vodafone Idea Limited (IDEA.BO) Income Statement Analysis – Financial Results
- Lok’nStore Group Plc (LOK.L) Income Statement Analysis – Financial Results
- Fitzroy River Corporation Limited (FZR.AX) Income Statement Analysis – Financial Results
- Gemtek Technology Co., Ltd. (4906.TW) Income Statement Analysis – Financial Results
- Pontem Corporation (PNTM-UN) Income Statement Analysis – Financial Results
Dyadic International, Inc. (DYAI)
About Dyadic International, Inc.
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.90M | 2.93M | 2.40M | 1.60M | 1.68M | 1.30M | 758.42K | 592.89K | 315.71K | 12.52M | 17.13M | 15.60M | 15.38M | 15.88M | 16.74M | 211.27K |
| Cost of Revenue | 1.98M | 2.12M | 1.94M | 1.42M | 1.46M | 1.03M | 680.20K | 516.16K | 124.01K | 8.18M | 9.72M | 7.62M | 11.35M | 12.86M | 12.83M | 175.44K |
| Gross Profit | 922.96K | 807.11K | 459.39K | 176.99K | 221.38K | 268.17K | 78.22K | 76.72K | 191.70K | 4.35M | 7.41M | 7.99M | 4.04M | 3.03M | 3.91M | 35.83K |
| Gross Profit Ratio | 31.84% | 27.54% | 19.11% | 11.05% | 13.17% | 20.70% | 10.31% | 12.94% | 60.72% | 34.71% | 43.25% | 51.18% | 26.25% | 19.05% | 23.34% | 16.96% |
| Research & Development | 3.30M | 4.50M | 8.39M | 3.87M | 3.96M | 3.32M | 2.20M | 885.60K | 124.01K | 2.19M | 1.00M | 921.71K | 4.24M | 4.90M | 3.62M | 0.00 |
| General & Administrative | 5.82M | 6.42M | 6.70M | 6.08M | 5.52M | 4.52M | 5.03M | 4.56M | 3.84M | 6.11M | 4.99M | 4.48M | 7.15B | 5.32M | 3.76M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.24M | 944.12K | 700.78K | 3.42B | 2.81M | 1.86M | 0.00 |
| SG&A | 5.82M | 6.42M | 6.70M | 6.08M | 5.52M | 4.52M | 5.03M | 4.56M | 3.84M | 7.36M | 5.94M | 5.50M | 10.57M | 8.13M | 5.61M | 42.54K |
| Other Expenses | 38.42K | 250.00K | 6.09M | 187.39K | 2.30M | 2.04M | 220.72K | 436.92K | 0.00 | 0.00 | 0.00 | 0.00 | -28.70K | -16.79K | 0.00 | 184.07K |
| Operating Expenses | 9.15M | 10.92M | 15.09M | 10.14M | 9.48M | 7.84M | 7.45M | 5.88M | 3.84M | 9.55M | 6.94M | 5.87M | 14.77M | 13.01M | 9.24M | 226.61K |
| Cost & Expenses | 11.13M | 13.05M | 17.03M | 11.57M | 10.94M | 8.87M | 8.13M | 6.40M | 3.96M | 17.72M | 16.66M | 13.49M | 26.12M | 25.87M | 22.07M | 402.05K |
| Interest Income | 416.69K | 180.42K | 51.70K | 447.00K | 984.93K | 0.00 | 0.00 | 485.49K | 11.16K | 28.06K | 14.61K | 695.85K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 894.53K | 566.15K | 909.00 | 11.16K | 683.21K | 686.02K | 0.00 | 594.16K | 710.54K | 597.91K | 0.00 |
| Depreciation & Amortization | 0.00 | 10.12M | 3.49M | 9.96M | 9.25M | 7.40M | 7.38M | 5.81M | -2.17M | 271.13K | 253.50K | 256.48K | 250.18K | 602.73K | 586.69K | 0.00 |
| EBITDA | -8.23M | -10.07M | -13.07M | -10.19M | -9.23M | -7.55M | -2.20M | 0.00 | -5.82M | -5.45M | 726.69K | 1.82M | -9.91M | -9.13M | -4.87M | -190.78K |
| EBITDA Ratio | -283.90% | -343.51% | -671.40% | -635.84% | -548.88% | -582.88% | -1,580.02% | -897.71% | -1,842.27% | -39.11% | 4.33% | 11.65% | -71.47% | -60.63% | -27.04% | -90.30% |
| Operating Income | -8.23M | -10.12M | -14.73M | -10.03M | -9.28M | -7.59M | -7.13M | -5.96M | -3.65M | -5.32M | 556.50K | 1.56M | -10.74M | -9.99M | -5.33M | -190.78K |
| Operating Income Ratio | -283.90% | -345.21% | -612.67% | -625.85% | -552.18% | -586.09% | -939.70% | -1,004.45% | -1,154.93% | -42.52% | 3.25% | 10.00% | -69.78% | -62.87% | -31.82% | -90.30% |
| Total Other Income/Expenses | 1.43M | 430.42K | 1.66M | 731.71K | 984.93K | 894.53K | 4.92M | 2.58M | 2.18M | 47.81K | -984.55K | -142.86K | -41.87K | -442.94K | -725.71K | 190.78K |
| Income Before Tax | -6.80M | -9.74M | -13.07M | -9.29M | -8.30M | -6.70M | -2.20M | -3.37M | -1.47M | -5.98M | -428.05K | 1.42M | -10.82M | -10.45M | -6.07M | 0.00 |
| Income Before Tax Ratio | -234.42% | -332.23% | -543.73% | -580.18% | -493.59% | -517.03% | -290.41% | -568.52% | -464.06% | -47.75% | -2.50% | 9.09% | -70.33% | -65.80% | -36.26% | 0.00% |
| Income Tax Expense | 0.00 | -364.37K | -148.60K | 31.32K | 10.31K | -1.01M | -66.69K | 238.07K | -69.44M | 127.39K | 229.83K | 68.00K | 63.11K | 64.23K | 9.71K | 190.78K |
| Net Income | -6.80M | -9.37M | -12.92M | -9.33M | -8.31M | -5.69M | -2.14M | -3.61M | 65.79M | -5.98M | -428.05K | 1.35M | -10.88M | -10.51M | -6.08M | -190.78K |
| Net Income Ratio | -234.42% | -319.79% | -537.54% | -582.13% | -494.21% | -439.36% | -281.61% | -608.67% | 20,837.76% | -47.75% | -2.50% | 8.65% | -70.74% | -66.20% | -36.32% | -90.30% |
| EPS | -0.24 | -0.33 | -0.46 | -0.34 | -0.31 | -0.21 | -0.07 | -0.10 | 1.91 | -0.18 | -0.01 | 0.04 | -0.45 | -0.48 | -0.42 | -0.04 |
| EPS Diluted | -0.24 | -0.33 | -0.46 | -0.34 | -0.31 | -0.21 | -0.07 | -0.10 | 1.91 | -0.18 | -0.01 | 0.04 | -0.45 | -0.48 | -0.37 | -0.04 |
| Weighted Avg Shares Out | 28.80M | 28.36M | 27.84M | 27.47M | 27.00M | 27.67M | 28.92M | 36.54M | 34.37M | 34.10M | 32.80M | 33.74M | 24.42M | 22.13M | 14.39M | 5.00M |
| Weighted Avg Shares Out (Dil) | 28.80M | 28.36M | 27.84M | 27.47M | 27.00M | 27.67M | 28.92M | 36.54M | 34.37M | 34.10M | 32.80M | 34.23M | 24.42M | 22.13M | 16.32M | 5.00M |
DYAI Stock Price Increases Over 54% Intraday: Why It Happened
The stock price of Dyadic International, Inc. (NASDAQ: DYAI) increased by over 54% during intraday trading. This is why it happened.
Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic's Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
JUPITER, Fla., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development,...
Dyadic to Report Second Quarter 2021 Financial Results
JUPITER, FL / ACCESSWIRE / July 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development,...
Best Penny Stocks to Buy Now? 4 to Watch During Earnings Season
With earnings season in full swing, which penny stocks are investors watching right now? The post Best Penny Stocks to Buy Now?
Dyadic Stock Shoots Higher On Technology Transfer, Licensing Pact For COVID-19 Vaccine In African Continent
Dyadic International Inc (NASDAQ: DYAI) stock is trading higher during the morning session on high volume after signing a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium. The South African-based company is focused on discovering, developing, evaluating, and manufacturing high-quality, cost-effective...
DYAI Stock Increases Over 62% Intraday: Why It Happened
The stock price of Dyadic International, Inc. (NASDAQ: DYAI) increased by over 62% during intraday trading. This is why it happened.
Dyadic Announces Technology Transfer and Licensing Agreement With South Africa's Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent
Potential for Affordable COVID-19 Immunization Coverage in Underserved African Countries Potential for Affordable COVID-19 Immunization Coverage in Underserved African Countries
Dyadic's C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal
JUPITER, Fla., June 28, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve...
Dyadic' Stock Jumps On COVID-19 Vaccine Development Pact In India
Dyadic International Inc (NASDAQ: DYAI) has collaborated with India-based Syngene International Limited to develop a COVID-19 vaccine candidate. The company says that the vaccine can potentially provide protection against the emerging variants and can be manufactured affordably, at an enormous scale, using...
DYAI Stock Price: Over 12% Increase Pre-Market Explanation
The stock price of Dyadic International, Inc. (NASDAQ: DYAI) increased by over 12% pre-market. This is why it happened.
Source: https://incomestatements.info
Category: Stock Reports